Sign In
Free Newsletter
Eagle Pharmaceuticals receives another delisting notice
Following multiple warnings for its failure to file forms on time, the Woodcliff Lake company said a hearings panel granted its request for continued listing on the market, subject to certain conditions.
Eagle Pharmaceuticals founder steps down
The Woodcliff Lake-based company has named Chairman of the Board Michael Graves as interim executive chairman of the board and interim principal executive officer.
Educational nonprofit recognizes work of 2 NJ honorees
Eagle Pharmaceuticals Inc. and Assistant U.S. Attorney NaSheena Porter Poznansky will be recognized by SEEDS-Access Changes Everything for their initiative and commitment to enhancing the opportunities for young people in the Garden State.
Eagle retains 20 Acacia employees post-acquisition
Of that team, Debra Hussain – who joined the target in 2021 as chief commercial officer – has been appointed senior vice president, head of commercial, for the Woodcliff Lake-based pharmaceutical company.
Eagle closes on $104M Acacia acquisition
The move adds two FDA-approved products to the Woodcliff Lake-based company’s portfolio: Barhemsys, used for the treatment of postoperative nausea and vomiting, and Byfavo, for procedural sedation in adults.
Why Eagle Pharmaceuticals is one to watch as economy recovers
The Woodcliff Lake-based company boasts a robust pipeline and just added two commercialized products through its acquisition of Acacia Pharma. In short, Eagle is ready to soar.
Eagle Pharmaceuticals to acquire UK-based Acacia Pharma
The target develops products designed to improve care for patients undergoing significant treatments such as surgery, other invasive procedures or chemotherapy.
